Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at The Longevity Therapeutics 2019 in San Francisco, 30 of January.
Artificial Intelligence (AI) techniques, such as deep learning (DL), reinforcement learning (RL), and generative adversarial networks (GANs) play a pivotal role in studying the biology of aging on many levels. The presentation will focus on the development of multi-modal predictors of age that use a variety of data types, ranging from blood tests to microbiomic and synthetic data, in order to give the most accurate biological age of the patient and identify actionable targets and pathways.
"We are happy to present our work at the Longevity Therapeutics, which gathers the key industry leaders. The topic of AI-powered end-to-end pipelines for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
Therapeutics Longevity Conference brings together all the leading biotech drug developers, academics, investors and pharma companies endeavoring to develop innovative therapies targeting age-related conditions. The Conference is held on 29-31 of January.
Source: http://www.insilicomedicine.com/
Natural killer cells lead the charge in cancer treatment innovation